Noxalk 150mg Capsule (Ceritinib)

Noxalk 150mg Capsule is a prescription-based targeted anticancer medicine that is used to treat specific types of non-small cell lung cancer (NSCLC) that have an abnormal ALK (anaplastic lymphoma kinase) gene. The active ingredient of Noxalk is ceritinib, which belongs to the drug class called "tyrosine kinase inhibitor" (TKI). It works by blocking abnormal ALK proteins that send growth signals that promote the division and replication of cancer cells. By inhibiting these signals, it helps slow or stop the progression and spread of cancer cells. A doctor conducts diagnostic testing to confirm the presence of an ALK alteration to progress in the therapy.

The capsule must be taken orally and swallowed whole with water and should not be crushed, chewed, or opened. The prescribed dose and duration of the ceritinib 150mg capsule depend on the patient's condition and response to treatment. It is taken with or without food as prescribed by the doctor. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include diarrhea, nausea, vomiting, abdominal pain, loss of appetite, tiredness, weight loss, and changes in liver function tests. A few patients can undergo severe side effects, including liver problems, inflammation of the lungs, heart rhythm abnormalities, and high blood sugar levels. Most of the ceritinib 150mg capsule side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

The capsule may harm an unborn baby, so pregnancy should be avoided during treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The ceritinib 150mg capsule must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Lung cancer

Like other anticancer medicines, Noxalk 150mg Capsule (Ceritinib 150mg) also has some common to severe side effects. These undesired symptoms are observed in the body after taking this medicine and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include the Following:
● Diarrhea
● Nausea
● Vomiting
● Fatigue
● Loss of appetite
● Abdominal pain
● Elevated liver enzymes (which may indicate liver issues)
● Headache
● Shortness of breath
● Rash
The above-mentioned effects don't need any special medical attention, but if you observe them continually, talk to your doctor immediately.

Take the Noxalk 150mg capsule (Ceritinib 150mg) in the exact dose as prescribed by the doctor. The typical dose of this capsule is once a day. It can be taken with or without food but at a fixed time each day to get better results. It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose on the medicine.

● Cooper, M. R., Chim, H., Chan, H., & Durand, C. (2015). Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Annals of Pharmacotherapy, 49(1), 107-112.
● Shaw, A. T., Kim, T. M., Crinò, L., Gridelli, C., Kiura, K., Liu, G., ... & Felip, E. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 18(7), 874-886.
● Dhillon, S., & Clark, M. (2014). Ceritinib: first global approval. Drugs, 74(11), 1285-1291.
● Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S., Brower, M., Fox, E., ... & Pazdur, R. (2015). FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase–positive non–small cell lung cancer. Clinical cancer research, 21(11), 2436-2439.
● Shaw, A. T., Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., ... & Engelman, J. A. (2014). Ceritinib in ALK-rearranged non–small-cell lung cancer. New England Journal of Medicine, 370(13), 1189-1197.